Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jeff Himawan Insider Profile
4 Followers
Jeff Himawan, Director at Gyre Therapeutics, holds 1.18M shares in Gyre Therapeutics (Ticker: GYRE), holds 11.70M shares in Medicinova (Ticker: MNOV), holds 0.00 shares in Horizon Therapeutics (Ticker: HZNP).
Jeff Himawan has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jeff Himawan
Jeff Himawan's Trading History
Gyre Therapeutics
Aug 20, 2015
Director
Uninformative Buy
―
$17.88M
Medicinova
―
Director
―
$15.68M
Horizon Therapeutics
Oct 06, 2023
―
Uninformative Sell
10.37M
$0.00
List of latest transactions for each holding click on a transaction to see Jeff Himawan's performance on stock
You May Also Like
Jeff Himawan insider profile FAQ
What is the percentage of profitable transactions made by Jeff Himawan?
The percentage of profitable transactions made by Jeff Himawan is ―.
What is the average return per transaction made by Jeff Himawan?
The average return per transaction made by Jeff Himawan is ―.
What stocks does Jeff Himawan hold?
Jeff Himawan holds: GYRE, MNOV, HZNP stocks.
What was Jeff Himawan’s latest transaction?
Jeff Himawan latest transaction was an Uninformative Buy of ―.
What was Jeff Himawan's most profitable transaction?
Jeff Himawan’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jeff Himawan's role in Gyre Therapeutics?
Jeff Himawan's role in Gyre Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.